AD Neural Stem Cell and Progenitor Therapy Companies

Alzheimer's Disease Neural Stem Cell and Progenitor Therapy Companies

Overview

Alzheimer's Disease Neural Stem Cell and Progenitor Therapy Companies

Overview

This page catalogs biotechnology and pharmaceutical companies developing neural stem cell (NSC) transplantation, neural progenitor cell (NPC) therapies, and endogenous NSC activation approaches for Alzheimer's disease (AD). These therapies focus on cell replacement and neural circuit reconstruction, distinct from broader cell therapy approaches and molecular neurogenesis promoters.

Key Distinctions

| Category | Focus | This Page |
|----------|-------|-----------|
| Neural Stem Cell Therapy | NSC/NPC transplantation, endogenous activation | ✓ Covered here |
| Cell Therapy (Broader) | MSCs, iPSC-derived various cells, microglia | See [AD Cell Therapy](/companies/ad-cell-therapy-companies) |
| Neurogenesis (Molecular) | Small molecules, biologics promoting neurogenesis | See [AD Neurogenesis](/companies/ad-neurogenesis-companies) |

Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| Allogeneic NSC Transplantation | Donor-derived neural stem cells for hippocampal replacement | Neuralstem, StemoniX |
| Autologous NSC Therapy | Patient-derived stem cells | Nostro Therapeutics |
| iPSC-Derived NPCs | Patient-specific neural progenitor cells | Aspen Neuroscience, Cellize |
| Endogenous NSC Activation | Activating brain's own neural stem cell niches | Neurowonder, Anagenesis |
| Neurotrophic Secreting Cells | Engineered cells producing BDNF, GDNF, NGF | Neurosphere, StemoniX |

Allogeneic Neural Stem Cell Transplantation

Neuralstem, Inc.

Status: Phase 1 Completed (AD), Discovery

Neuralstem, Inc. is a pioneer in neural stem cell therapy, developing NSI-566, a human spinal cord-derived neural stem cell line. The company has completed a Phase 1 trial for AD and continues to explore NSC transplantation approaches.

• Product: NSI-566 (human neural stem cells)
• Source: Spinal cord-derived NSCs
• Mechanism: Neuronal replacement, neurotrophic factor secretion (BDNF, NGF), synaptic integration
• Delivery: Intracerebral transplantation to hippocampal region
• Clinical Status: Phase 1 completed (NCT03072134), exploring next trials

StemoniX Inc.

Status: Preclinical

StemoniX is a biotechnology company developing microbrain® and axon® platforms for neural disease modeling and therapy. Their approach combines human iPSC-derived neural cells with proprietary aggregation technology for functional neural tissue generation.

• Platform: microbrain® (3D neural spheroids)
• Cell Type: iPSC-derived neural progenitor cells
• Mechanism: Neuronal replacement, neural circuit reconstruction
• Applications: AD modeling, drug screening, therapeutic transplantation

iPSC-Derived Neural Progenitor Cell Therapies

Aspen Neuroscience

Status: Preclinical (AD program)

Aspen Neuroscience is developing autologous iPSC-derived neural cells for AD, with a focus on cholinergic neuron replacement for basal forebrain restoration.

• Approach: Autologous iPSC-derived neural progenitor cells
• Target: Basal forebrain cholinergic neurons (BFCNs)
• Advantage: Patient-matched cells reduce immune rejection risk
• Status: Preclinical

Cellize Inc.

Status: Discovery

Cellize is a biotechnology company focused on iPSC-derived cell therapies for neurodegenerative diseases. Their platform specializes in neural progenitor cell differentiation and large-scale manufacturing.

• Platform: iPSC to NPC differentiation technology
• Target: AD, PD applications
• Mechanism: Controlled differentiation to desired neuronal subtypes
• Status: Discovery

Endogenous NSC Activation

Neurowonder Therapeutics

Status: Discovery

Neurowonder Therapeutics is developing small molecule and biologic approaches to activate endogenous neural stem cells in the adult brain. Their focus is on the subventricular zone (SVZ) and subgranular zone (SGZ) niches.

• Approach: Endogenous NSC activation
• Target: SVZ and SGZ neurogenic niches
• Mechanism: Pathway modulation to promote NSC proliferation and differentiation
• Status: Discovery

Anagenesis Biotechnologies

Status: Preclinical

Anagenesis is developing regenerative medicine approaches for neurological disorders, with a focus on endogenous stem cell activation and tissue engineering.

• Approach: Endogenous stem cell activation
• Platform: Small molecule modulators of stem cell niches
• Target: CNS regeneration
• Status: Preclinical

Neurotrophic Factor-Secreting Cell Lines

Neurosphere Therapeutics

Status: Discovery

Neurosphere Therapeutics is focused on developing cell-based therapies that combine neural progenitor cells with engineered neurotrophic factor expression.

• Approach: NPC engineering for enhanced neurotrophic secretion
• Factors: BDNF, GDNF, NGF
• Mechanism: Combined cell replacement and trophic support
• Status: Discovery

Company Summary Table

| Company | Approach | Development Stage | Key Mechanism |
|---------|----------|------------------|---------------|
| Neuralstem | Allogeneic NSCs | Phase 1 Completed | Neuronal replacement, neurotrophic secretion |
| StemoniX | iPSC-derived NPCs | Preclinical | 3D neural spheroids, circuit reconstruction |
| Aspen Neuroscience | Autologous iPSC-NPCs | Preclinical | Cholinergic neuron replacement |
| Cellize | iPSC to NPC platform | Discovery | Controlled differentiation |
| Neurowonder | Endogenous NSC activation | Discovery | Niche pathway modulation |
| Anagenesis | Endogenous stem cell activation | Preclinical | Small molecule niche modulators |
| Neurosphere Therapeutics | NPCs + neurotrophic factors | Discovery | Combined replacement and trophic support |

Clinical Trials in NSC/NPC Therapy for AD

| Company | Product | Phase | NCT Number | Status |
|---------|---------|-------|------------|--------|
| Neuralstem | NSI-566 | Phase 1 | NCT03072134 | Completed |

Cross-Linking Context

This page complements and is distinct from related category pages:

• [AD Cell Therapy Companies](/companies/ad-cell-therapy-companies) — Broader cell therapy category including MSCs, microglia, astrocyte therapy
• [AD Neurogenesis Companies](/companies/ad-neurogenesis-companies) — Molecular approaches to promote neurogenesis (small molecules, biologics)
• [Parkinson's Disease Cell Therapy](/companies/pd-cell-therapy-companies) — Parallel approaches for PD
• [Neurogenesis Pathway](/mechanisms/neurogenesis-ad) — Molecular mechanisms of neurogenesis
• [Neural Stem Cell Biology](/mechanisms/neural-stem-cells) — Biology of NSCs and neurogenic niches

References

See Also

• [TDP-43 Protein](/wiki/proteins-tar-db-protein) — associated_with